These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8131448)

  • 41. Implications of fibrinogenolysis in patients with closed head injury.
    Kushimoto S; Shibata Y; Yamamoto Y
    J Neurotrauma; 2003 Apr; 20(4):357-63. PubMed ID: 12866815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction.
    Lee LV; Ewald GA; McKenzie CR; Eisenberg PR
    Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):628-33. PubMed ID: 9108774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Degradation products of fibrinogen and fibrin in bacteremia due to gram-negative rods.
    Satterwhite TK; Hawiger J; Burklow SL; Koenig MG
    J Infect Dis; 1973 Apr; 127(4):437-41. PubMed ID: 4694546
    [No Abstract]   [Full Text] [Related]  

  • 44. Prototype quantitative assay for fibrinogen/fibrin degradation products. Clinical evaluation.
    Sigal SH; Cembrowski GS; Shattil SJ; Brown NM; Schifreen RS; Schwartz MW
    Arch Intern Med; 1987 Oct; 147(10):1790-3. PubMed ID: 3662708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Critical evaluation of new methods for studying fibrin degradation products].
    Prisco D
    Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased serum concentration of soluble CD14 is a prognostic marker in gram-positive sepsis.
    Burgmann H; Winkler S; Locker GJ; Presterl E; Laczika K; Staudinger T; Knapp S; Thalhammer F; Wenisch C; Zedwitz-Liebenstein K; Frass M; Graninger W
    Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 1):307-10. PubMed ID: 8811052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokine screening identifies NICU patients with Gram-negative bacteremia.
    Raynor LL; Saucerman JJ; Akinola MO; Lake DE; Moorman JR; Fairchild KD
    Pediatr Res; 2012 Mar; 71(3):261-6. PubMed ID: 22278182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum procalcitonin in diagnosis of bacteremia.
    Jongwutiwes U; Suitharak K; Tiengrim S; Thamlikitkul V
    J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S79-87. PubMed ID: 19562990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Assay of products of fibrin and fibrinogen degradation in disseminated intravascular coagulations. Evaluation of a new technique].
    Borschneck C; Dreyfus M; Bridey F; Edouard D; Meyer D
    Presse Med; 1995 May 6-13; 24(17):799-802. PubMed ID: 7630868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Fibrinogen degradation products, soluble fibrin and antithrombin III in toxic goiter patients].
    Panchenko VM; Salakhidinov Z; Khaĭkina MB
    Probl Endokrinol (Mosk); 1979; 25(1):11-5. PubMed ID: 581702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma cross-linked fibrin degradation product (XLFbDP) assays in an in vivo model of fibrinolysis.
    Rowbotham BJ; Whitaker AN; Masci PP
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):653-61. PubMed ID: 2133245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
    Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
    Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibrinogen and fibrin degradation products in patients undergoing open-heart surgery.
    Rifón J; Fernández J; Páramo JA; Cuesta B; Rocha E
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):509-12. PubMed ID: 2133228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
    Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M
    Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
    Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
    Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group.
    Bates DW; Parsonnet J; Ketchum PA; Miller EB; Novitsky TJ; Sands K; Hibberd PL; Graman PS; Lanken PN; Schwartz JS; Kahn K; Snydman DR; Moore R; Black E; Platt R
    Clin Infect Dis; 1998 Sep; 27(3):582-91. PubMed ID: 9770160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct].
    Belousov IuB; Panchenko EP; Pivovarov VA; Nemiro VK
    Kardiologiia; 1979 Aug; 19(8):87-91. PubMed ID: 491364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Nosocomial bacteremia].
    Samet A; Bronk M; Sledzińska A; Labon M; Rybak B
    Przegl Epidemiol; 2006; 60(1):35-41. PubMed ID: 16758736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.